(EMAILWIRE.COM, May 30, 2019 ) According to the new market research report “Antinuclear Antibody Test Market by Product (Reagents & Assay Kits, Systems, Software, Services), Technique (Immunofluorescence, Elisa, Multiplex), Disease (Rheumatoid Arthritis, SLE), End User (Clinical Labs, Hospitals) — Forecast ”, published by MarketsandMarkets™.

The increasing prevalence of autoimmune diseases and increasing healthcare expenditure worldwide are the major factors driving the growth of this market.

This report segments this ANA testing market based on products, diseases, techniques, end users, and regions. In the product's market, the assay kits & reagents segment is expected to account for the largest share. This segment is also expected to grow at the highest CAGR during the forecast period due to the growth in the number of reagent rental agreements and the increasing prevalence of autoimmune diseases worldwide.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=218189007

Browse and in-depth TOC on “Antinuclear Antibody Test Market”

73 — Tables

102 — Figures

166 — Pages

Based on techniques, the Antinuclear Antibody Test Market is segmented into three broad segment, namely, enzyme-linked immunosorbent assay (ELISA), immunofluorescence assay (IFA), and multiplex assay. The ELISA segment is expected to account for the largest share of this market owing to expanding applications of ANA in autoimmune disease testing and therapeutic drug level monitoring.

The Antinuclear Antibody Test Market’s end-user segments in this market include clinical laboratories, hospitals, POLs, and other end users. The hospitals segment is expected to account for the largest share in 2016, primarily due to the rising healthcare spending which has resulted in a growth in use of ANA testing products in hospitals.

Request for Free Sample Report @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=218189007

Key players in the Antinuclear Antibody Test Market include Alere Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), ERBA Diagnostics, Inc. (U.S.), Trinity Biotech plc (Ireland), Thermo Fisher Scientific, Inc. (U.S.), Antibodies, Inc. (U.S.), EUROIMMUN AG (Germany), Immuno Concepts (U.S.), Inova Diagnostics (U.S.), and Zeus Scientific, Inc. (U.S.).